Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | CCKBR | P32239 | 6/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP4 | P49662 | 1/20 | 0.49 |
| ▸ | CASP5 | P51878 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 4/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914602 | 0.90 | MAGI3 (0.60) | MAGI3OPRD1OPRM1ACECCKBR | |
| SCHEMBL30903449 | 0.89 | OPRD1 (0.53) | MAGI3OPRD1OPRM1ACECCKBR | |
| SCHEMBL30051300 | 0.88 | ACE (0.60) | OPRD1OPRM1ACEERAP2ECE1 | |
| SCHEMBL30051762 | 0.85 | ACE (0.56) | OPRD1OPRM1ACEECE1 | |
| SCHEMBL31462103 | 0.85 | GLP1R (0.58) | MAGI3ERAP2ECE1 | |
| SCHEMBL30596170 | 0.85 | ERAP2 (0.64) | CCKBRERAP2CCKAR | |
| SCHEMBL30834724 | 0.84 | OPRM1 (0.56) | OPRD1OPRM1ACEERAP2ECE1 | |
| SCHEMBL30563211 | 0.84 | MME (0.49) | OPRD1OPRM1ACE | |
| SCHEMBL29351947 | 0.84 | ACE (0.60) | MAGI3ACEERAP2ECE1 | |
| SCHEMBL29366452 | 0.84 | PCSK9 (0.52) | MAGI3OPRD1OPRM1ACECCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240309058-A1 | TUMOR HOMING AND CELL PENETRATING PEPTIDE-IMMUNO-ONCOLOGY AGENT COMPLEXES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2024-09-19 | — | — | US | disclosed |
| US-20240287147-A1 | PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2024-08-29 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11866466-B2 | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | Blaze Bioscience, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | MAGI3 979/4885OPRD1 3705/4885OPRM1 3161/4885 |
| US-20240309058-A1 | TUMOR HOMING AND CELL PENETRATING PEPTIDE-IMMUNO-ONCOLOGY AGENT COMPLEXES AND METHODS OF USE THEREOF | TAP1, CXCL12, CCL2 | MAGI3 2949/4885OPRD1 3514/4885OPRM1 1668/4885 |
| US-20240287147-A1 | PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | MAGI3 3900/4885OPRD1 1859/4885OPRM1 2099/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | MAGI3 979/4885OPRD1 3705/4885OPRM1 3161/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | MAGI3 979/4885OPRD1 3705/4885OPRM1 3161/4885 |
| US-11866466-B2 | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | TAP1, CXCL12, CCL2 | MAGI3 2949/4885OPRD1 3514/4885OPRM1 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.